Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Debré P[au]:

[Challenges set by the microbiota]. Debré P et al. Biol Aujourdhui. (2017)

The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. Ringel O et al. Viruses. (2018)

The francophone network on neglected tropical diseases. Jannin J et al. PLoS Negl Trop Dis. (2017)

Search results

Items: 1 to 50 of 409

1.

HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial.

Vieillard V, Combadière B, Tubiana R, Launay O, Pialoux G, Cotte L, Girard PM, Simon A, Dudoit Y, Reynes J, Rockstroh J, Garcia F, Gatell J, Devidas A, Yazdanpanah Y, Weiss L, Fätkenheuer G, Autran B, Joyeux D, Gharakhanian S, Debré P, Katlama C.

NPJ Vaccines. 2019 Jun 3;4:25. doi: 10.1038/s41541-019-0117-5. eCollection 2019.

2.

Persistence of dysfunctional natural killer cells in adults with high-functioning autism spectrum disorders: stigma/consequence of unresolved early infectious events?

Bennabi M, Tarantino N, Gaman A, Scheid I, Krishnamoorthy R, Debré P, Bouleau A, Caralp M, Gueguen S, Le-Moal ML, Bouvard M, Amestoy A, Delorme R, Leboyer M, Tamouza R, Vieillard V.

Mol Autism. 2019 May 15;10:22. doi: 10.1186/s13229-019-0269-1. eCollection 2019.

3.

Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope.

Dorgham K, Pietrancosta N, Affoune A, Lucar O, Bouceba T, Chardonnet S, Pionneau C, Piesse C, Sterlin D, Guardado-Calvo P, Karoyan P, Debré P, Gorochov G, Vieillard V.

J Immunol Res. 2019 Mar 24;2019:9804584. doi: 10.1155/2019/9804584. eCollection 2019.

4.

Molecularly Imprinted Polymer Nanoparticles as Potential Synthetic Antibodies for Immunoprotection against HIV.

Xu J, Merlier F, Avalle B, Vieillard V, Debré P, Haupt K, Tse Sum Bui B.

ACS Appl Mater Interfaces. 2019 Mar 13;11(10):9824-9831. doi: 10.1021/acsami.8b22732. Epub 2019 Feb 27.

PMID:
30758939
5.

HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2+ NK cells in Lassa virus infection.

Wauquier N, Petitdemange C, Tarantino N, Maucourant C, Coomber M, Lungay V, Bangura J, Debré P, Vieillard V.

EBioMedicine. 2019 Feb;40:605-613. doi: 10.1016/j.ebiom.2019.01.048. Epub 2019 Jan 30.

6.

B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.

Lucar O, Sadjo Diallo M, Bayard C, Samri A, Tarantino N, Debré P, Thiébaut R, Brun-Vézinet F, Matheron S, Cheynier R, Vieillard V; ANRS CO5 IMMUNOVIR-2 Study group.

AIDS. 2019 Jan 27;33(1):23-32. doi: 10.1097/QAD.0000000000002061.

PMID:
30325780
7.

Genetic screening of male patients with primary hypogammaglobulinemia can guide diagnosis and clinical management.

Vince N, Mouillot G, Malphettes M, Limou S, Boutboul D, Guignet A, Bertrand V, Pellet P, Gourraud PA, Debré P, Oksenhendler E, Théodorou I, Fieschi C; DEFI Study Group.

Hum Immunol. 2018 Jul;79(7):571-577. doi: 10.1016/j.humimm.2018.04.014. Epub 2018 Apr 27.

PMID:
29709555
8.

The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.

Ringel O, Vieillard V, Debré P, Eichler J, Büning H, Dietrich U.

Viruses. 2018 Apr 15;10(4). pii: E197. doi: 10.3390/v10040197. Review.

9.

[Xe International Congress of the Société de pathologie exotique, 8-9 November 2017, Haiphong (Vietnam) - Surgery Access in Tropical Areas].

Buisson Y, Guyon P, Buisson Y, Osinki N, Tamames C, Leconte J, Jarry M, Robert J, Dumurgier C, Choua O, Ahmat MO, Moussa KM, Sabe D, Telniaret A, Rabo AM, Kitoko N, Allatombaye B, Bunn D, Hong Dao N, Huy LD, Bich Ngoc HL, Tram LH, Van Khoi T, Van Thuc P, Van Linh P, Kourouma K, Gerald FT, Kourouma K, Saibou PO, Ngunyi GC, Wombe B, Alessandroni P, Andrei R, Delmont J, Gasiglia C, Haï VV, Heng M, Heng T, Khampho C, Mekhalfa D, Marcaggi S, Pimontipa M, Plotton JR, The Ngo NA, Vilayphone T, Duong TX, Hoa NL, Pays JF, Buchy P, Goujon C, Bouchaud O, Consigny PH, de Gentile L, D'Ortenzio E, Gautret P, Sorge F, Strady C, Pichard E, Haddar C, Bégaud E, Yuh MY, Law EL, Germani Y, Bouchaud O, Houze S; groupe d’étude MalaRia, Chandenier J, Jannin J, Solano P, Quick I, Debre P, Guyon P, Ensaf A, Bourée P, Fabre-Teste B, El Mouden M, Soula G.

Bull Soc Pathol Exot. 2017 Dec;110(5):353-354. doi: 10.1007/s13149-017-0586-6. French. No abstract available.

PMID:
29299881
10.

Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller.

Ringel O, Müller K, Koch J, Brill B, Wolf T, Stephan C, Vieillard V, Debré P, Dietrich U.

AIDS Res Hum Retroviruses. 2018 Apr;34(4):365-374. doi: 10.1089/AID.2017.0250. Epub 2018 Jan 25.

11.

[Louis Pasteur and Claude Bernard: about a posthumous controversy].

Debré P.

Biol Aujourdhui. 2017;211(2):161-164. doi: 10.1051/jbio/2017019. Epub 2017 Dec 13. French.

PMID:
29236666
12.

The francophone network on neglected tropical diseases.

Jannin J, Solano P, Quick I, Debre P.

PLoS Negl Trop Dis. 2017 Aug 31;11(8):e0005738. doi: 10.1371/journal.pntd.0005738. eCollection 2017 Aug. No abstract available.

13.

Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.

Lucar O, Su B, Potard V, Samri A, Autran B, Moog C, Debré P, Vieillard V.

EBioMedicine. 2017 Aug;22:122-132. doi: 10.1016/j.ebiom.2017.07.007. Epub 2017 Jul 11.

14.

[Challenges set by the microbiota].

Debré P.

Biol Aujourdhui. 2017;211(1):19-28. doi: 10.1051/jbio/2017012. Epub 2017 Jul 6. Review. French.

PMID:
28682224
15.

[The microbiota's challenges].

Debré P.

Med Sci (Paris). 2016 Nov;32(11):919-920. doi: 10.1051/medsci/20163211001. Epub 2016 Dec 23. French. No abstract available.

16.

Perspectives for immunotherapy: which applications might achieve an HIV functional cure?

Vieillard V, Gharakhanian S, Lucar O, Katlama C, Launay O, Autran B, Ho Tsong Fang R, Crouzet J, Murphy RL, Debré P.

Oncotarget. 2016 Jun 21;7(25):38946-38958. doi: 10.18632/oncotarget.7793. Review.

17.

Accumulation of Intrahepatic TNF-α-Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection.

Nel I, Lucar O, Petitdemange C, Béziat V, Lapalus M, Bédossa P, Debré P, Asselah T, Marcellin P, Vieillard V.

Medicine (Baltimore). 2016 May;95(19):e3678. doi: 10.1097/MD.0000000000003678.

18.

Longitudinal Analysis of Natural Killer Cells in Dengue Virus-Infected Patients in Comparison to Chikungunya and Chikungunya/Dengue Virus-Infected Patients.

Petitdemange C, Wauquier N, Devilliers H, Yssel H, Mombo I, Caron M, Nkoghé D, Debré P, Leroy E, Vieillard V.

PLoS Negl Trop Dis. 2016 Mar 3;10(3):e0004499. doi: 10.1371/journal.pntd.0004499. eCollection 2016 Mar.

19.

Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer.

Peraldi MN, Berrou J, Venot M, Chardiny V, Durrbach A, Vieillard V, Debré P, Charron D, Suberbielle C, Chevret S, Glotz D, Dulphy N, Toubert A.

Transplantation. 2015 Nov;99(11):2422-30.

PMID:
26798861
20.

[Towards a vaccine against HIV: antibodies raised by a gp41 peptide neutralize the virus and inhibit pathogenesis].

Vieillard V, Debré P.

Biol Aujourdhui. 2015;209(2):161-6. doi: 10.1051/jbio/2015019. Epub 2015 Oct 29. Review. French.

PMID:
26514385
21.

Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation.

Baychelier F, Achour A, Nguyen S, Raphael M, Toubert A, Besson C, Arnoux A, Roos-Weil D, Marty M, Chapelier A, Samuel D, Debré P, Vieillard V; Study of Cancers After Solid Organs Transplants (K-GREF) Study Group.

J Heart Lung Transplant. 2015 Apr;34(4):604-12. doi: 10.1016/j.healun.2014.09.038. Epub 2014 Oct 2.

PMID:
25476847
22.

[Intestinal microbiota].

Debré P, Le Gall JY; commission I (Biologie).

Bull Acad Natl Med. 2014 Dec;198(9):1667-84. French.

PMID:
27356369
23.

[Translational research: An ambition to share with hospital biomedical sector].

Debré P.

Presse Med. 2014 Oct;43(10 Pt 1):1080-2. doi: 10.1016/j.lpm.2014.07.004. Epub 2014 Sep 4. French. No abstract available.

PMID:
25201594
24.

Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors.

Achour A, Baychelier F, Marty M, Debré P, Samuel D, Vieillard V.

Oncoimmunology. 2014 Apr 29;3:e28782. eCollection 2014.

25.

NKp44L: A new tool for fighting cancer.

Vieillard V, Baychelier F, Debré P.

Oncoimmunology. 2014 Jan 1;3(1):e27988. Epub 2014 Feb 14.

26.

A polysaccharide virulence factor of a human fungal pathogen induces neutrophil apoptosis via NK cells.

Robinet P, Baychelier F, Fontaine T, Picard C, Debré P, Vieillard V, Latgé JP, Elbim C.

J Immunol. 2014 Jun 1;192(11):5332-42. doi: 10.4049/jimmunol.1303180. Epub 2014 Apr 30.

27.

Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients.

Régent A, Autran B, Carcelain G, Cheynier R, Terrier B, Charmeteau-De Muylder B, Krivitzky A, Oksenhendler E, Costedoat-Chalumeau N, Hubert P, Lortholary O, Dupin N, Debré P, Guillevin L, Mouthon L; French Idiopathic CD4 T Lymphocytopenia Study Group.

Medicine (Baltimore). 2014 Mar;93(2):61-72. doi: 10.1097/MD.0000000000000017.

28.

[Genome sequencing and personalized medicine: perspectives and limitations].

Le Gall JY, Debré P; Commission I (Biologie).

Bull Acad Natl Med. 2014 Jan;198(1):101-17. French.

PMID:
26259290
29.

Expansion of CMV-mediated NKG2C+ NK cells associates with the development of specific de novo malignancies in liver-transplanted patients.

Achour A, Baychelier F, Besson C, Arnoux A, Marty M, Hannoun L, Samuel D, Debré P, Vieillard V; K-GREF Study Group.

J Immunol. 2014 Jan 1;192(1):503-11. doi: 10.4049/jimmunol.1301951. Epub 2013 Dec 4.

30.

NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy.

Sennepin A, Baychelier F, Guihot A, Nel I, Ho Tsong Fang R, Calin R, Katlama C, Simon A, Crouzet J, Debré P, Vieillard V.

AIDS. 2013 Jul 31;27(12):1857-66.

PMID:
24179999
31.

Constitutive expression of ligand for natural killer cell NKp44 receptor (NKp44L) by normal human articular chondrocytes.

Białoszewska A, Baychelier F, Niderla-Bielińska J, Czop A, Debré P, Vieillard V, Kieda C, Malejczyk J.

Cell Immunol. 2013 Sep-Oct;285(1-2):6-9. doi: 10.1016/j.cellimm.2013.08.005. Epub 2013 Sep 3.

PMID:
24044960
32.

Identification of a cellular ligand for the natural cytotoxicity receptor NKp44.

Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debré P, Vieillard V.

Blood. 2013 Oct 24;122(17):2935-42. doi: 10.1182/blood-2013-03-489054. Epub 2013 Aug 19.

33.

A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion.

Petitdemange C, Achour A, Dispinseri S, Malet I, Sennepin A, Ho Tsong Fang R, Crouzet J, Marcelin AG, Calvez V, Scarlatti G, Debré P, Vieillard V.

Clin Infect Dis. 2013 Sep;57(5):745-55. doi: 10.1093/cid/cit335. Epub 2013 May 21.

PMID:
23696512
34.

[Genetic control of infectious diseases: from Mendel's laws to exome sequencing].

Debré P, Le Gall JY.

Bull Acad Natl Med. 2013 Jan;197(1):157-71. Review. French.

PMID:
24672987
35.

An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques.

Vieillard V, Dereuddre-Bosquet N, Mangeot-Méderlé I, Le Grand R, Debré P.

Vaccine. 2012 Nov 6;30(48):6883-91. doi: 10.1016/j.vaccine.2012.09.004. Epub 2012 Sep 16.

PMID:
22989687
36.

Specific anti-gp41 antibodies predict HIV-1 disease progression.

Vieillard V, Crouzet J, Boufassa F, Sennepin A, Ho Tsong Fang R, Debré P, Meyer L.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):403-5. doi: 10.1097/QAI.0b013e318264b307.

PMID:
22732471
37.

Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.

Curriu M, Fausther-Bovendo H, Pernas M, Massanella M, Carrillo J, Cabrera C, López-Galíndez C, Clotet B, Debré P, Vieillard V, Blanco J.

PLoS One. 2012;7(2):e30330. doi: 10.1371/journal.pone.0030330. Epub 2012 Feb 1.

38.

Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infection.

Guergnon J, Dalmasso C, Broet P, Meyer L, Westrop SJ, Imami N, Vicenzi E, Morsica G, Tinelli M, Zanone Poma B, Goujard C, Potard V, Gotch FM, Casoli C, Cossarizza A, Macciardi F, Debré P, Delfraissy JF, Galli M, Autran B, Costagliola D, Poli G, Theodorou I, Riva A; GISHEAL Consortium.

J Infect Dis. 2012 Mar 1;205(5):718-24. doi: 10.1093/infdis/jir833. Epub 2012 Jan 11.

PMID:
22238471
39.

Toward a transdisciplinary understanding and a global control of emerging infectious diseases.

Gonzalez JP, Lambert G, Legand A, Debré P.

J Infect Dev Ctries. 2011 Dec 13;5(12):903-5.

40.

CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients.

Béziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debré P, Björkström NK, Malmberg KJ, Marcellin P, Vieillard V.

Eur J Immunol. 2012 Feb;42(2):447-57. doi: 10.1002/eji.201141826. Epub 2011 Dec 16.

41.

Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity.

Petitdemange C, Becquart P, Wauquier N, Béziat V, Debré P, Leroy EM, Vieillard V.

PLoS Pathog. 2011 Sep;7(9):e1002268. doi: 10.1371/journal.ppat.1002268. Epub 2011 Sep 22.

42.

CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation.

Béziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, Combadière B, Debré P, Vieillard V.

J Immunol. 2011 Jun 15;186(12):6753-61. doi: 10.4049/jimmunol.1100330. Epub 2011 May 9.

43.

Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease.

Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, Musset L, Debré P, Amoura Z, Vieillard V.

Arthritis Rheum. 2011 Jun;63(6):1698-706. doi: 10.1002/art.30313.

44.

Expression and proliferative effect of hemokinin-1 in human B-cells.

Grassin-Delyle S, Buenestado A, Vallat L, Naline E, Marx S, Decocq J, Debré P, Bernard OA, Advenier C, Devillier P, Merle-Béral H.

Peptides. 2011 May;32(5):1027-34. doi: 10.1016/j.peptides.2011.02.012. Epub 2011 Feb 18.

PMID:
21334411
45.

Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.

Nguyen S, Béziat V, Norol F, Uzunov M, Trebeden-Negre H, Azar N, Boudifa A, Bories D, Debré P, Vernant JP, Vieillard V, Dhédin N.

Transfusion. 2011 Aug;51(8):1769-78. doi: 10.1111/j.1537-2995.2010.03058.x. Epub 2011 Feb 18.

PMID:
21332732
46.

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.

Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL, Merle-Beral H, Vieillard V.

Leukemia. 2011 Jan;25(1):101-9. doi: 10.1038/leu.2010.240. Epub 2010 Oct 26.

PMID:
20975664
47.

NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.

Béziat V, Descours B, Parizot C, Debré P, Vieillard V.

PLoS One. 2010 Aug 6;5(8):e11966. doi: 10.1371/journal.pone.0011966.

48.

HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway.

Fausther-Bovendo H, Vieillard V, Sagan S, Bismuth G, Debré P.

PLoS Pathog. 2010 Jul 1;6:e1000975. doi: 10.1371/journal.ppat.1000975.

49.

Human NK cells display major phenotypic and functional changes over the life span.

Le Garff-Tavernier M, Béziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debré P, Merle-Beral H, Vieillard V.

Aging Cell. 2010 Aug;9(4):527-35. doi: 10.1111/j.1474-9726.2010.00584.x. Epub 2010 May 10.

50.

B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease.

Mouillot G, Carmagnat M, Gérard L, Garnier JL, Fieschi C, Vince N, Karlin L, Viallard JF, Jaussaud R, Boileau J, Donadieu J, Gardembas M, Schleinitz N, Suarez F, Hachulla E, Delavigne K, Morisset M, Jacquot S, Just N, Galicier L, Charron D, Debré P, Oksenhendler E, Rabian C; DEFI Study Group.

J Clin Immunol. 2010 Sep;30(5):746-55. doi: 10.1007/s10875-010-9424-3. Epub 2010 May 1.

PMID:
20437084

Supplemental Content

Support Center